BioCentury
ARTICLE | Clinical News

Novartis reports Phase II data for malaria compound

August 1, 2014 12:41 AM UTC

Novartis AG (NYSE:NVS; SIX:NOVN) said once-daily oral KAE609 for three days led to a median parasite clearance time, the primary endpoint, of 12 hours in an open-label Phase II trial to treat malaria. The Thai trial enrolled 21 adults with uncomplicated Plasmodium vivax or P. falciparum malaria, including patients with resistant infections. The trial was conducted in collaboration with The Wellcome Trust-Mahidol University-Oxford Tropical Medicine Research Programme. Data were published in the New England Journal of Medicine.

Novartis said Phase IIb trials with KAE609 are being planned, but the pharma did not provide a time frame on when the trials are slated to start in time for publication. KAE609 is a synthetic spiroindolone analog. ...